OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House
This article was originally published in The Pink Sheet
Executive Summary
With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.
You may also be interested in...
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
Indiana Ups State Power To Limit Pseudoephedrine Product Sales
DEA has the authority and expertise to conduct stress tests on pseudoephedrine formulations, says CHPA state government director Carol Gutierrez. But Indiana allows its pharmacy board to say whether a PSE product is tamper-resistant.